Addvalue Technologies

SINGAPORE (June 29): Addvalue Technologies and Inmarsat have signed an agreement to implement the first constellation of Inter-Satellite Data Relay System (IDRS) equipped satellites for an unidentified “leading satellite operator”.

SINGAPORE (June 19): Addvalue Technologies and KGI Securities (Singapore) have mutually agreed to terminate with immediate effect the placement agreement announced on April 30.

SINGAPORE (June 7): Addvalue Technologies has finally started to commercialise its key flagship technology, the inter-satellite data relay system (IDRS), which has been under development and testing for more than three years.

SINGAPORE (June 7): Addvalue Technologies confirmed it has entered into an airtime service agreement with an existing customer for the latter to provide enhanced data gathering services to its clients.

SINGAPORE (Apr 27): NRA Capital says Addvalue Technologies is likely to rake in some US$10 million ($13.3 million) in revenue from its first major commercial Inter-Satellite Data Relay System (IDRS) contract win earlier this week.

SINGAPORE (Apr 25): Addvalue Technologies has inked its first major commercial Inter-Satellite Data Relay System (IDRS) contract with a satellite service provider for the customised design and supply of IDRS terminals, which are to be installed on the cus

SINGAPORE (Mar 12): Addvalue Technologies has signed a collaboration agreement with Kongsberg Satellite Services (KSAT) to “work closely together to provide enhanced communications services in support of small low orbiting satellite operations”.

SINGAPORE (Feb 8): NRA Capital says loss-making satellite communications player Addvalue Technologies could well be back on the growth track soon.

SINGAPORE (Jan 2): Addvalue Technologies is making inroads into the Russian market with its Thuraya Atlas IP terminal.

SINGAPORE (Oct 5): Addvalue Technologies, the mobile satellite communications provider, is in a partnership to offer its maritime product and data solutions bundle to deep-sea fishing vessels in a test trial.